Jakob Dupont
CIK 1553335 · EVP, Head of R&D · last filed 2026-07-02
Jakob Dupont is an EVP, Head of R&D who has filed 51 SEC Form 4 insider transactions across 5 companies since 2019. The most recent filing, for PYXS, was dated Jul 2, 2026. Across all open-market trades the lifetime net is −$1.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $213.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$213.1K
5
51
-$1.31M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PYXS | Director | 38,741 | $2.91 | $112.7K | -$107.1K | 6 | 2026-07-02 |
| BOLT | Director | — | $4.02 | — | $0 | 5 | 2026-06-11 |
| ATRA | EVP, Head of R&D | 11,632 | $7.81 | $90.8K | -$573.0K | 15 | 2023-03-06 |
| Apexigen, Inc. (APGNW) Delisted | Director | — | $0.03 | — | $0 | 1 | 2022-10-03 |
| GOSS | Chief Medical Officer | 46,500 | $0.21 | $9.5K | -$631.5K | 3 | 2020-02-19 |
Recent Filings
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | PYXS | Mixed | — | -$51.1K | EDGAR |
| 2026-06-30 | PYXS | Notice (144) | −35,000 | -$107.0K | EDGAR |
| 2026-06-11 | BOLT | Grant (A) | — | $0 | EDGAR |
| 2026-03-25 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2025-12-16 | BOLT | Mixed | — | $0 | EDGAR |
| 2025-07-02 | BOLT | Grant (A) | — | $0 | EDGAR |
| 2025-05-05 | BOLT | Grant (A) | — | $0 | EDGAR |
| 2025-04-02 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2024-09-06 | BOLT | Grant (A) | — | $0 | EDGAR |
| 2024-03-28 | PYXS | Grant (A) | +38,741 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.